ANIKA THERAPEUTICS, INC.

Consensus Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 09:49:59 2026-03-11 am EDT			5-day change	1st Jan Change
14.16 ^USD	-2.04%		+1.81%	+52.13%

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT

Evolution of the Average Target: Anika Therapeutics, Inc.

Evolution of the Target Price: Anika Therapeutics, Inc.

Changes in Analyst Recommendations: Anika Therapeutics, Inc.

f2ea1e6dec64caf05207b3.lQT21QeEoLVshpbDI0C_nGEuGOMM4edioPP-xEgppnA.326zuk_vy4JfvqOCbxborBVxb9NjqN8m8Lubozwf0i_CYsGAafTI1gnZ0w~6cd56932fc5a0957a4a7d76241d650aa

Analysts' recommendations: Anika Therapeutics, Inc.

Feb. 27	Barrington Adjusts Price Target on Anika Therapeutics to $17 From $16, Maintains Outperform Rating	MT
Feb. 27	B. Riley Adjusts Price Target on Anika Therapeutics to $18 From $16, Maintains Buy Rating	MT
25-07-30	Anika Therapeutics Q2 revenue falls 8%; Hyalofast trial misses main goal	RE
25-05-12	Barrington Adjusts Anika Therapeutics Price Target to $19 From $20, Maintains Outperform Rating	MT
25-04-17	B. Riley Initiates Anika Therapeutics at Buy With $21 Price Target	MT
24-03-14	Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating	MT
24-01-04	Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating	MT
23-11-03	Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating	MT
23-08-14	Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Saying 'Downdraft in Shares Seems Materially Overdone,' Price Target is $24	MT
23-08-10	Stephens Adjusts Price Target on Anika Therapeutics to $23 From $28, Maintains Equal-Weight Rating	MT
23-03-07	Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform After Full-Year 2023 Forecast Below Expectations	MT
23-03-07	Barrington Research Downgrades Anika Therapeutics to Market Perform From Outperform	MT
22-11-09	Barrington Upgrades Anika Therapeutics to Outperform From Market Perform, Price Target is $31	MT
22-10-14	Stephens Reinstates Anika Therapeutics at Equalweight With $26 Price Target	MT
22-03-09	Stephens Downgrades Anika Therapeutics to Equalweight from Overweight, Adjusts Price Target to $35 from $50	MT
21-11-16	Stephens Starts Anika Therapeutics at Overweight With $55 Price Target	MT
21-11-05	Barrington Adjusts Price Target on Anika Therapeutics to $48 From $44, Keeps Outperform Rating	MT
21-07-16	ANIKA THERAPEUTICS : UBS Starts Anika Therapeutics at Neutral With $46 Price Target	MT
20-12-16	ANIKA THERAPEUTICS : Barrington Research Upgrades Anika Therapeutics to Outperform From Market Perform; Price Target is $43	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ANIKA THERAPEUTICS, INC.			-		+21.02%
	ABBOTT LABORATORIES					+20.61%
	MEDTRONIC PLC					+24.25%
	CENCORA, INC.					+16.41%
	HOYA CORPORATION					+1.19%
	BECTON, DICKINSON AND COMPANY					+20.3%
	DEXCOM, INC.					+26.64%
	STERIS PLC					+26.64%
	TERUMO CORPORATION					+44.7%
	Average					+22.42%
	Weighted average by Cap.					+20.12%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

2

Last Close Price

14.46USD

Average target price

17.50USD

Spread / Average Target

+21.02%

High Price Target

18.00USD

Spread / Highest target

+24.48%

Low Price Target

17.00USD

Spread / Lowest Target

+17.57%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Barrington Research
B. Riley
Stephens Inc.
UBS

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

2

Last Close Price

14.46USD

Average target price

17.50USD

Spread / Average Target

+21.02%

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Equities
ANIK Stock
Consensus Anika Therapeutics, Inc.

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW